Department of Oncology, Tom Baker Cancer Center, University of Calgary, 1331-29th Street North West, Calgary, AB, Canada T2N 4N2.
The current treatment paradigm for metastatic renal cell carcinoma (RCC) includes agents that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. Because these agents have revolutionized RCC over the past five years, new clinical and molecular predictive and prognostic tools are required. These are potentially important for therapy selection, patient counseling, and clinical trial stratification. This review examines clinical prognostic models and molecular biomarkers in RCC.
Written by:
Tang PA, Vickers MM, Heng DY. Are you the author?
Reference: Hematol Oncol Clin North Am. 2011 Aug;25(4):871-91.
doi: 10.1016/j.hoc.2011.04.003
PubMed Abstract
PMID: 21763972
UroToday.com Renal Cancer Section
